Research and development - AOI #19 for the development of novel oxygen therapeutic NAN02 for COVID19: extend
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00034
- Awardee
-
Nuvox Pharma, L.L.C. UEI WHNYG96UDLJ8
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $356,447
Award facts
- Opportunity
-
- EZBAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $356,447.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Tucson, AZ 85719, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$393,000 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,447 |
About this award
Nuvox Pharma, L.L.C., a small disadvantaged business based in Tucson, Arizona, was awarded a $356,447.48 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services. The contract, awarded on July 28, 2023, extends previous research under Announcement of Opportunity #19 for the development of novel oxygen therapeutic nanoparticles (NANO2) for COVID-19 treatment. The contract has no set-aside designation and is scheduled for completion by May 31, 2025. Research and development services will be performed at the contractor's facility in Tucson, Arizona.
This contract represents a continuation of Nuvox Pharma's specialized work in advanced medical nanotechnology research, building upon the company's established expertise in oxygen therapeutic interventions. ASPR's investment in NANO2 development aligns with the agency's mission to strengthen preparedness and response capabilities for public health emergencies. The contractor's current federal portfolio includes multiple grants from the National Institutes of Health and Defense Health Agency focused on expanding NANO2 applications across oncology, neurology, and immunotherapy, demonstrating the broader clinical potential of the technology being developed under this contract.
Quick answers
Who was awarded contract 75A50123C00034?
75A50123C00034 was awarded to Nuvox Pharma, L.L.C. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 28, 2023.
How much is contract 75A50123C00034 worth?
The government has obligated $356,447 on 75A50123C00034.
Was contract 75A50123C00034 competed?
The extent of competition for 75A50123C00034 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award